SLU-PP-332 vs Tesamorelin

SLU-PP-332

A synthetic small-molecule pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ), not a peptide. It is marketed as an "exercise mimetic" because in mice it increased oxidative metabolism, running endurance and fat oxidation and reduced fat gain on a high-fat diet without changing food intake. That is the entire evidence base: preclinical rodent and cell work from academic labs. There are NO human trials, no human pharmacokinetics, no human safety data and no published human dosing whatsoever — nothing here is derived from a study in people. It is sold as 1 mg oral tablets, so the 500-1000 mcg (0.5-1 mg) daily range shown is simply half a tablet to one tablet: a deliberately narrow, conservative reading of vendor packaging, not a validated dose. Human half-life is unknown, so it is left null rather than guessed. It is swallowed as tablets rather than reconstituted, so the reconstitution fields do not apply. Treat every number on this page as the lowest possible confidence.

Tesamorelin

The only compound in this class with a real FDA label. Tesamorelin is a stabilised GHRH (1-44) analogue approved as Egrifta to reduce excess visceral abdominal fat in HIV-infected patients with lipodystrophy, supported by two phase 3 randomized placebo-controlled trials over 26 weeks with a 26-week extension. Label dosing is 2 mg subcutaneously once daily (Egrifta and Egrifta SV); the reformulated Egrifta WR is 1.28 mg once daily, which is why the range here starts at 1280 mcg. Approved dosing applies ONLY to that HIV lipodystrophy indication - use for general body composition, and any product bought as a research chemical, is off-label and unapproved. Not studied in and not indicated for weight loss in the general population. Note that the Egrifta label directs administration immediately after reconstitution with the supplied diluent; the 30-day figure here reflects bacteriostatic-water reconstitution of multi-dose vials, which is not a labeled practice.